Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Wisconsin is set to give Eli Lilly up to $100 million in Enterprise Zone tax credits for its $3 billion expansion in Bristol ...

Under the terms of the agreement, Eli Lilly is to make double-digit million-dollar upfront payments and invest in LTZ’s equity. In addition, LTZ is entitled to receive preclinical, clinical, ...

Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based state tax credits for its $4 billion investment in Wisconsin.